Stephanie S. Faubion, MD, on choosing between fezolinetant and elinzanetant, liver monitoring, follow-up, and open questions in menopause care.
|Videos|December 27, 2022
Scynexis CEO talks recent ibrexafungerp approval
Author(s)Morgan Ebert
Marco Taglietti, MD, president and CEO of Scynexis, sits with Contemporary OB/GYN® to discuss the recent approval of ibrexafungerp (Brexafemme) for the reduction in incidence of recurrent vulvovaginal candidiasis.
Advertisement
Advertisement
Related to this article
JoAnn V. Pinkerton, MD, MSCP, reviews 4 pooled elinzanetant analyses from OASIS presented at The Menopause Society Annual Meeting 2026, spanning late perimenopause, sleep, VMS reduction, and safety.
The FDA approved the first generic of Climara Pro, a weekly estradiol/levonorgestrel patch for VMS and osteoporosis prevention in women with a uterus.
In September, the FDA accepted an extended duration sNDA for the IUD with a decision expected in Q2 2027.
Pritelivir healed all HSV lesions by day 28 in 63% of immunocompromised adults vs 34% with comparators.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Before Pregnancy Begins: Why the Timing of Carrier Screening Matters
2
JoAnn V. Pinkerton, MD, MSCP, on elinzanetant across menopause subpopulations at TMS 2026
3
Brain fog at menopause: Separating normal change from dementia
4
What to expect at The Menopause Society's 2026 Annual Meeting
5